Top Stories
Oorja Bio launched with $30 million and an idiopathic pulmonary fibrosis candidate, while MaaT expects a negative opinion on its acute graft-versus-host disease candidate in Europe.
The combined firm will back companies across pharmaceuticals, medical devices, life science tools, diagnostics, healthcare infrastructure and healthcare IT.
After 16 weeks, 35.8% of patients taking weekly IMVT-1402 achieved ACR70.
CANOPY-HCH-3 demonstrates significant growth velocity improvement with the modified C-type natriuretic peptide over placebo.
One of the drugmaker's main goals is to make its wealth of scientific, clinical, regulatory and commercial expertise easy to surface.
Conference News
– Positive CardiAMP CMI Trial open-label cohort results demonstrated opportunity for locally delivered cell therapy to enhance therapeutic options for patients with severely symptomatic refractory ang...
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare...
SAN DIEGO, May 21, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent st...
Long-term and real-world evidence reinforce BRUKINSA as the foundation of CLL treatmentThree oral presentations at ASCO highlight rapid acceleration of BeOne’s solid tumor pipelineSAN CARLOS, Calif.--...
Study met its primary objective demonstrating excellent safety and tolerability, of RESP-X in patients with NCFB colonised with Pseudomonas aeruginosa (Pa)Secondary objectives met with no immunogenici...
